Senti Biosciences (SNTI) said Monday enrollment in the investigator-sponsored trial for SENTI-301A, a treatment for hepatocellular carcinoma, has been paused.
The study is being conducted in partnership with Celest Therapeutics (Shanghai) Co. in China and uses Senti's SENTI-301A gene circuit in Chimeric Antigen Receptor Natural Killer cells manufactured by Celest. The trial was halted after dose-limiting toxicities were observed. Senti Bio is currently evaluating next steps for the program as part of a broader pipeline prioritization effort, the company said.
The company also reported additional preliminary data from its phase 1 trial of SENTI-202, an investigational off-the-shelf CAR-NK cell therapy that is being developed for the treatment of relapsed or refractory hematologic cancers, including acute myeloid leukemia.
In the dose-finding stage, SENTI-202 was well tolerated, with no dose-limiting toxicities reported and no maximum tolerated dose reached, and a preliminary recommended phase 2 dose was identified. The trial is ongoing, with continued enrollment to confirm the preliminary RP2D and expand into disease-specific groups, the company said.
The company also shared preliminary, unaudited financial results for Q1. The company reported a net loss of $14.1 million, or $1.41 per share, for the quarter ended March 31. Final results will be released in its upcoming 10-Q filing, expected around May 6.
Shares of Senti Biosciences fell past 22% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。